DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Israel, MD
Valeant Pharmaceuticals North America LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
60 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Hospital
Phoenix, Arizona, United States
- Mayo Clinic Arizona
Scottsdale, Arizona, United States
- City of Hope Medical Center
Duarte, California, United States
- Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
- Genesis Research
San Diego, California, United States
- Stanford University Hospital
Stanford, California, United States
- University of Colorado, Anschutz Cancer Pavilion
Aurora, Colorado, United States
- the Urology Center of Colorado
Denver, Colorado, United States
- Neag Comprehensive Cancer Center/university of Connecticut Health Center
Farmington, Connecticut, United States
- Yale University School of Medicine
New Haven, Connecticut, United States
- Urological Research Network
Hialeah, Florida, United States
- University of Miami Cancer Center
Miami, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute, Inc.
Tampa, Florida, United States
- American Red Cross
Atlanta, Georgia, United States
- Emory Department of Urology, the Emory Clinic Inc, Emory University Hospital
Atlanta, Georgia, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Indiana University
Indianapolis, Indiana, United States
- Kansas City Urology Care
Overland Park, Kansas, United States
- University of Kansas Cancer Center
Westwood, Kansas, United States
- Johns Hopkins Hospital
Baltimore, Maryland, United States
- the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Lahey Clinic
Burlington, Massachusetts, United States
- Michigan Institute of Urology
Troy, Michigan, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Gu Research Center, Llc
Omaha, Nebraska, United States
- John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Columbia University Medical Center
New York, New York, United States
- Memorial Sloan Kettering
New York, New York, United States
- Mount Sinai School of Medicine
New York, New York, United States
- Mount Sinai School of Medicine Department of Urology
New York, New York, United States
- Nyu Clinical Cancer Center, Nyu Langone Medical Center
New York, New York, United States
- Weill Cornell Medical College
New York, New York, United States
- Associated Medical Professionals of Ny, Pllc
Oneida, New York, United States
- University of Rochester Medical Center
Rochester, New York, United States
- Associated Medical Professionals of New York, Pllc
Syracuse, New York, United States
- Unc Health Care, Nc Cancer Hospital
Chapel Hill, North Carolina, United States
- Duke University
Durham, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2011
- Primary completion
- 31 Jul 2015
- Completion
- 31 Jul 2015
- Last update posted
- 25 May 2017
- Registered enrollment
- 142
- Registry id
- NCT01353222
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.